Novosense(SH:688052) Zheng Quan Zhi Xing·2025-06-13 13:19Core Viewpoint - The company plans to use remaining over-raised funds amounting to RMB 71,926.68 million for permanent working capital supplementation, subject to shareholder approval [1][5][6]. Fundraising Overview - The company was approved to publicly issue 25,266,000 shares at RMB 230.00 per share, raising a total of RMB 581,118.00 million, with a net amount of RMB 558,124.66 million after deducting issuance costs [2][4]. - The total amount of over-raised funds is included in the overall fundraising total [5]. Fund Usage Plan - The company intends to use the remaining over-raised funds to meet working capital needs, improve fund utilization efficiency, reduce financial costs, and enhance profitability [4][5][6]. - The company commits to using no more than 30% of the total over-raised funds for permanent working capital supplementation within any 12-month period [5][6]. Approval Process - The proposal to use the remaining over-raised funds was approved in the 18th meeting of the third board of directors and the supervisory board on June 13, 2025, and is pending shareholder meeting approval [2][6][7]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the use of over-raised funds for working capital, stating it aligns with regulations and does not harm shareholder interests [6]. - The sponsor also confirms that the proposal has followed necessary procedures and complies with relevant regulations [6][7].